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During vertebrate embryonic development, cardiac and skeletal muscle originates from distinct precursor populations.
Despite the profound structural and functional differences in the striated muscle tissue they eventually form, such
progenitors share many features such as components of contractile apparatus. In vertebrate embryos, the -cardiac actin
gene encodes a major component of the myofibril in both skeletal and cardiac muscle. Here, we show that expression of
Xenopus cardiac -actin in the myotomes and developing heart tube of the tadpole requires distinct enhancers within its
proximal promoter. Using transgenic embryos, we find that mutations in the promoter-proximal CArG box and 5 bp
downstream of it specifically eliminate expression of a GFP transgene within the developing heart, while high levels of
expression in somitic muscle are maintained. This sequence is insufficient on its own to limit expression solely to the
myocardium, such restriction requiring multiple elements within the proximal promoter. Two additional enhancers are
active in skeletal muscle of the embryo, either one of which has to interact with the proximal CArG box for correct
expression to be established. Transgenic reporters containing multimerised copies of CArG box 1 faithfully detect most sites
of SRF expression in the developing embryo as do equivalent reporters containing the SRF binding site from the c-fos
promoter. Significantly, while these motifs possess a different A/T core within the CC(A/T)6GG consensus and show no
similarity in flanking sequence, each can interact with a myotome-specific distal enhancer of cardiac -actin promoter, to
confer appropriate cardiac -actin-specific regulation of transgene expression. Together, these results suggest that the role
of CArG box 1 in the cardiac -actin gene promoter is to act solely as a high-affinity SRF binding site. © 2002 Elsevier
Science (USA)
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In all vertebrates, skeletal muscle is derived from paraxial
mesoderm, while cardiac muscle progenitors form from a
distinct region of anterolateral mesoderm. The relative
timing of skeletal and cardiac differentiation varies be-
tween different vertebrate classes, reflecting different strat-
egies for embryonic development. For mammalian em-
bryos, an early dependence on the maternal supply of
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All rights reserved.nutrients and the requirements of gas exchange both neces-
sitate rapid development of a functional cardiovascular
system. In contrast, embryos of most fish and amphibia
require skeletal muscle early during embryogenesis in order
to swim, while the cardiovascular system develops rela-
tively slowly, being required only later in larval stages of
development.
During skeletal muscle differentiation, critical early roles
are played by myogenic factors belonging to the basic–loop–
helix family, including MyoD and Myf5. These factors are
remarkable since not only are they required for skeletal
muscle development in the embryo, but their expression is
also sufficient to convert nonmyogenic cell type into myo-
tubes in culture. Myogenic factors execute their roles, at
least in part, by transactivating skeletal muscle-specific
differentiation genes, and by down-regulating genes in-8906-4977. E-mail:tmohun@nimr.mrc.ac.uk.57
volved in cell cycle and growth control (Puri and Sartorelli,
2000). In contrast, no cardiogenic factors of equivalent
potency have, so far, been described. Instead, numerous
studies on regulation of cardiac-specific genes suggest that
their transcription is regulated in a more complex manner,
mediated by several families of transcription factors, none
of which is strictly restricted to myocardial muscle tissue.
The homeobox gene Nkx2.5, MADS family proteins MEF2
and Serum Response Factor (SRF), along with the zinc-
finger factors GATA 4–6 have all been implicated in
regulation of myocardial-specific genes (Fishman and
Chien, 1997; Mohun and Sparrow, 1997). These transcrip-
tion factors appear to act in concert in a variety of combi-
nations to transactivate their target genes. Although poorly
understood, the basis of their interaction is most likely the
formation of heterodimers, or even higher-order complexes
(Belaguli et al., 2000; Biesiada et al., 1999; Chen and
Schwartz, 1996; Morin et al., 2000, 2001).
In addition to having a role in regulating expression of
cardiac differentiation genes, each of these transcription
factors is involved in other developmental pathways or
differentiated cell types. For example, Nkx2.5 is involved in
development of the pharynx (Tanaka et al., 2001), GATA-4
in gut formation (Zaret, 1999), and MEF2 in skeletal muscle
differentiation (Black and Olson, 1998; Puri and Sartorelli,
2000). SRF in particular, has been implicated in the regula-
tion of diverse transcriptional pathways. As well as partici-
pating in skeletal and cardiac muscle differentiation, it also
plays a role in the regulation of genes that are inducible by
serum growth factors and other extracellular stimuli (Tre-
isman, 1995). In each role, SRF acts by binding to a DNA
recognition site of consensus sequence CC(A/T)6GG
(termed CArG box), present in the regulatory regions of its
targets (Treisman, 1995).
How is specificity of SRF function achieved when the
protein can regulate such a large number of dissimilar target
genes in different cellular and developmental contexts?
Studies to date have suggested that SRF activity is likely to
be regulated on several levels. Of critical importance is the
capacity of SRF to interact directly with numerous acces-
sory proteins. For example, ETS-family proteins such as
Elk-1 simultaneously bind SRF and a sequence adjacent to
the serum response element (SRE) in the promoters of
several cellular immediate-early genes, including the c-fos
proto-oncogene (Treisman, 1994). This ternary complex
mediates the response of c-fos to a range of stimuli (Treis-
man, 1994). Additionally, experiments with cultured cells
indicate that SRF can interact with tissue-restricted cofac-
tors such as MyoD (Groisman et al., 1996) and GATA-4
(Belaguli et al., 2000; Morin et al., 2001), and such interac-
tions may play a role in restricting activity of SRF during
muscle differentiation in vivo. Posttranslational modifica-
tions of SRF protein are also known to regulate its activity
and can be triggered by such diverse stimuli as growth
factors and cytoskeletal actin polymerisation (Sotiropoulos
et al., 1999; Treisman, 1995). Finally, multiple splicing
pathways for the SRF gene transcript may produce function-
ally distinct products, including at least one that appears to
possess dominant-negative activity (Belaguli et al., 1999;
Kemp and Metcalfe, 2000).
Among striated muscle-specific genes identified as tar-
gets of SRF, one of the best studied is the cardiac -actin
gene. This encodes a major structural component of the
striated muscle myofibril in vertebrate embryos. Four con-
served CArG boxes are present in the promoters of the
human, mouse, chick, and amphibian genes along with
binding sites for the MyoD family of myogenic factors.
Previous studies have identified the most proximal CArG
box as essential for activity of the human cardiac -actin
promoter in cultured cardiomyocytes, and a combination of
this CArG box and adjacent binding sites for SP1 and MyoD
are necessary for activation of the cardiac -actin promoter
in differentiating myogenic cell lines (Biesiada et al., 1999;
Sartorelli et al., 1990). In Xenopus, microinjected copies of
the gene require the proximal CArG box and a distal
myogenic factor binding site for expression in embryo
explants that have been induced to form skeletal muscle
(Mohun et al., 1989b). In transgenic mouse embryos, a
proximal enhancer of the mouse gene, including the four
CArG boxes, is sufficient for correct but weak expression of
a transgene, while more distal sequences are required for
appropriate expression in the adult (Biben et al., 1996).
Since the cardiac -actin gene is activated during forma-
tion of both cardiac and skeletal muscle in vertebrates, its
study may also shed light on the mechanisms that distin-
guish terminal differentiation in these two muscle types. In
previous studies, we have examined expression of a reporter
driven by the cardiac -actin gene promoter using a direct
DNA injection assay (Mohun et al., 1989b). However,
injected episomal DNA is unstable in embryos, and while
we were able to examine expression of the reporter in
embryonic skeletal muscle, we were unable to extended the
assay to monitor expression in the developing heart. Trans-
genesis (Kroll and Amaya, 1996) overcomes such limita-
tions and we have now used this approach to delineate
sequences necessary for transgene expression in striated
muscle of the embryo. Our results indicate that distinct but
overlapping sets of regulatory sequences are responsible for
expression of the cardiac -actin gene in myotomal and
cardiac muscle.
MATERIAL AND METHODS
Recombinant DNA
A series of 8-bp linker scan (LS) mutations have been described
previously (Mohun et al., 1989b). An internal deletion, LS10/13,
was constructed by replacing the KpnI-EcoRI fragment from LS13
with the equivalent fragment from LS10. All cardiac -actin
promoter variants were cloned in front of a reporter comprising the
mGFP5 coding region and the SV40 polyadenylation sequence
(Sparrow et al., 2000a).
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Heterologous Promoter Fusions
A minimal promoter fragment comprising 48 bp of the cytoskel-
etal actin promoter (Mohun and Garrett, 1987) was fused to the
mGFP5/SV40 cassette; an equivalent construct comprising the
thymidine kinase minimal promoter has been described previously
(Sparrow et al., 2000a).
The following oligonucleotides were used to construct synthetic
promoters comprising sequences from the cardiac -actin pro-
moter: CArG box 1 L; TACCAAATAAGGGTCACCTGCCTTTCC:
CArG box 1 R; TACCAAATAAGGGCAGGCTATGATTCC: CArG
Box 1  DS; TACCAAATAAGGGCAGGCTGCCTTTCC: mut
Box 1-5; CTACCAAATTTGGGCAGGCTGCCTTTCC: mut Box
1-6; CTACCTTTTAAGGGCAGGCTGCCTTTCC: E-CArG box 1;
GCACCTGTCTACTCCATTTGCCAAATAAGGGCAGGC; c-fos
SRE oligo sequence: GGATGTCCATATTAGGACATCT (Taylor
et al., 1989). Complementary oligonucleotides were annealed and
cloned in vectors (as indicated) via KpnI or Asp718 cohesive ends.
All constructs were sequenced to establish the number and orien-
tation of oligonucleotide copies cloned.
A promoter fragment spanning nucleotides 275/92 of the
cardiac -actin promoter was amplified by PCR. pF711 comprises
the entire human c-fos gene and promoter; pF100 possesses a
truncated promoter in which sequences upstream of 100 (includ-
ing the SRE) have been removed (Treisman, 1985). Cardiac -actin
promoter variants were cloned as EcoRI/BamHI fragments in front
of pF100.
Xenopus Embryo Manipulations
Blastula animal pole explants were dissected from Xenopus
embryos and treated with activin as described previously (Sive,
2000; Smith et al., 1988). DNA injections were performed at the
two-cell stage by using 100 pg of DNA (Mohun et al., 1989a).
Transgenic embryos were generated according to method of
Amaya and Kroll (Kroll and Amaya, 1996), with modifications as
described (Sparrow et al., 2000b). To confirm successful generation
of transgenic embryos when using very weak or inactive cardiac
-actin promoter variants, we included a -crystallin/GFP reporter
(Offield et al., 2000) with the test construct. We found that using an
equimolar ratio of the full-length cardiac -actin/GFP and
-crystallin/GFP reporters, approximately 75% of transgenic em-
bryos coexpressed both transgenes.
Analysis of Transgene Expression
Embryos expressing GFP were analysed either by direct observa-
tion of fluorescence or by whole-mount in situ hybridisation to
detect GFP mRNA (Sparrow et al., 2000a). GFP activity in trans-
genic embryos was documented by using a CoolSnap digital camera
(Roper Scientific) attached to a Leica MZFLIII dissecting micro-
scope with fluorescence illumination. Images were processed in
Adobe Photoshop 5.0 and weak expression resolved from back-
ground autofluorescence by using the “auto levels” function. This
procedure transforms the green colour of GFP fluorescence to blue,
which is then readily distinguished from auto-fluorescence of yolk,
which acquires an orange–yellow colour. Whole-mount in situ
hybridisation was performed as previously described (Harland,
1991), with probes specific for GFP (Sparrow et al., 2000a) and XSRF
(Mohun et al., 1991). A second XSRF probe encompassing the 3
half of the cDNA gave identical results to those presented here.
Electrophoretic Mobility Shift Analysis
Double-stranded oligonucleotides with 5GTAC overhangs (20
ng) were labelled with [-32P]-dCTP and Klenow DNA polymerase
as described (Sambrook, 1989). Human SRF (Norman et al., 1988)
was translated in vitro by using a coupled transcription-translation
system (Promega) according to manufacturer’s instructions. Bind-
ing reactions and competitions were as described (Norman et al.,
1988).
Oligonucleotides used for probes and competition assays are
described above, except CArG mut (see Fig. 6B): CTAGGAAATA-
AGGGCAGGCTGCCTTTC.
Cell Transfections and RNase Protection Assays
Serum stimulation assays using transfected NIH3T3 cells were
performed and analysed by RNase protection assays exactly as
described previously (Taylor et al., 1989), using the expression of a
transfected -globin construct as an internal reference (Treisman,
1985).
RESULTS
580 bp of Cardiac -actin Promoter Is Sufficient to
Recapitulate the Endogenous Expression Pattern
during Embryonic Development
In previous studies, 580 bp of the cardiac -actin pro-
moter were sufficient to confer high levels of reporter gene
expression from episomal, plasmid DNA in skeletal muscle
derived from Xenopus embryonic tissue (Mohun et al.,
1989b). We therefore tested the activity of the same pro-
moter fragment fused to a green fluorescent protein (GFP)
reporter in transgenic frog embryos. GFP expression was
first seen in the somites during neurula stages (Figs. 1A and
1C), and subsequently detected in cardiac, facial, body wall
and tail muscles (Figs. 1B, 1D–1G). In later embryos, trans-
gene expression was also detected in developing limb buds
(data not shown).
We next tested the ability of activin to induce expression
of the GFP transgene in animal pole explants from F1
transgenic embryos. By the time sibling control embryos
had reached neurula stages, GFP expression was readily
detected in the explants treated with activin, confirming
that skeletal muscle differentiation was induced (Figs. 1H
and 1I). Similarly, the cardiac -actin GFP transgene pro-
vided a sensitive marker for cardiac muscle differentiation.
Prolonged culture of anteroventral tissue explants encom-
passing the heart field of early tailbud embryos (Sater and
Jacobson, 1990) resulted in the formation of primitive heart
tubes. These were readily visible by GFP fluorescence (Fig.
1K) long before their detection was possible by morphology
alone. Larger explants subsequently developed facial and
body wall muscles, patterned in a manner remarkably
similar to that detected in the whole embryo (Figs. 1J and
1K). These results demonstrate that 580 bp of proximal
promoter sequence direct spatiotemporal expression during
embryogenesis in a manner indistinguishable from the
endogenous gene.
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CArG Box1 and Immediate Proximal Sequences
Are Necessary for Expression in the Heart
We next tested the effect of individual 8-bp linker scan
mutations on expression of the cardiac actin-GFP transgene
in skeletal and cardiac muscle of transgenic embryos.
Surprisingly, our results proved strikingly different from
those obtained by direct DNA injection. In those studies,
mutation of CArG box 1 (linker scan mutation LS29)
abolished any expression of the reporter in embryonic
skeletal muscle (Mohun et al., 1989b). By contrast, when
tested by transgenesis, the same mutation had little or no
apparent effect on GFP expression in the myotomes, rather
it selectively abolished later expression in differentiating
heart muscle (Fig. 2D). Mutation of flanking sequences
immediately upstream of CArG box1 (LS25) had no compa-
rable effect but, unexpectedly, an equivalent mutation
affecting proximal flanking nucleotides (LS13) also resulted
in specific reduction or loss of heart-specific expression
(Figs. 2C and 2E).
The Xenopus gene contains two other CArG motifs
upstream of CArG box 1, each of which can bind SRF
(Taylor et al., 1989) and functionally replace CArG box 1
when moved to the equivalent position in the promoter.
Not surprisingly, removal of all CArG boxes by deletion of
sequences from 216 to 80 (internal deletion LS10/13)
also abolished expression of the transgene in cardiac muscle
(Fig. 3A). Insertion of two copies of a short oligonucleotide
comprising only CArG box 1 and the immediate down-
stream sequence into the internal deletion was sufficient to
restore strong levels of transgene expression in the tadpole
heart (Fig. 3B). Furthermore, the temporal pattern of trans-
gene expression was comparable with that of the full-length
promoter (data not shown).
explants from F1 transgenic embryos cultured in the absence (H) or
presence (I) of 8 U/ml activin until sibling embryos reached stage
24. GFP activity is only seen in animal caps treated with activin,
demonstrating that the transgene is activated by the mesoderm-
inducing signal. GFP expression can be used to monitor heart and
head muscles in explants from F1 transgenic embryos. (J) Stage 34
control embryo, ventral view, anterior to the right. Strong expres-
sion is detected in the heart (arrow) and head muscles (arrow
heads). (K) A heart field explant excised at stage 22, oriented in the
same way as an embryo in (J).
FIG. 2. E-boxes are dispensable for normal expression of cardiac
-actin in embryos, while CArG box 1 and sequence immediately
downstream of it are necessary for expression in the heart. (A)
Deletion of sequences upstream of 216 results in expression
indistinguishable from that obtained with the entire 580-bp pro-
moter. (B) 5-103 is expressed in the heart but not in the myo-
tomes. It also gives inappropriate expression in the head. (C) Linker
scan mutation LS25 shows no effect on expression. (D) In contrast,
LS29, which destroys CArG box 1, results in loss of heart expres-
sion. (E) A sequence downstream of CArG box 1 is essential for
expression in the heart, as revealed by linker scan mutation LS13.
FIG. 1. A portion of cardiac -actin promoter that is 580 bp is
sufficient for correct expression in Xenopus embryos, tadpoles, and
explants. (Top) Schematic presentation of 580 cardiac -actin
promoter. Transgene expression can be detected in the somites of
the late neurula embryo and in myotomes, facial muscle and heart
(h) of the larval tadpole, either by whole-mount in situ for GFP
RNA (A, B) or by GFP fluorescence (C, D). (E) GFP activity in the
tail of 7-day-old tadpole. (F) Ventral view of a 7-day-old tadpole,
showing strong GFP activity in the heart (boxed), body wall, and
jaw muscles. Anterior is to the right. (G) Close-up of the heart
region boxed in (G). ot, outflow tract; v, ventricle. (H, I) Animal cap
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FIG. 3. (A) Internal deletion LS10/13 removes CArG boxes 1-4, resulting in weak expression in the myotomes and loss of expression in
the heart. (B) An oligonucleotide comprising CArG box 1 and the adjacent 10 bp downstream are sufficient to restore normal expression
to LS10/13. (C), L-LS10/13, in which 5 bp most proximal to CArG box 1 are changed, is not expressed in the heart but is expressed normally
in the myotomes. (D) Mutation of the more distal 5 bp has no effect on transgene activity in the heart. (E) Mutant T-LS10/13 shows
expression in the myotomes, but not in the heart (arrow). (Transgenic constructs shown in B–E all contain two copies of the
oligonucleotides; see Table 1.)
FIG. 4. CArG Box 1  DS is sufficient for expression in myotomes and head and heart region. (A) A chimeric construct comprising
oligonucleotide CArG Box 1  DS adjacent to the minimal cytoskeletal actin promoter gave expression in the myotomes, heart (arrowed), and
branchial arches of the stage 33 tadpole. (B) Similar expression was obtained with this oligonucleotide in front of the thymidine kinase minimal
promoter. (C) However, at earlier stages, transgene expression directed by CArG Box 1  DS is premature and too broad, as seen in the
presumptive heart field of stage 22 embryo. (D, F) Using either the cardiac actin or cytoskeletal actin basal promoter, an E-box placed adjacent
to the CArG box 1DS restricts activity of transgene to the myotomes. No expression is seen in the heart (arrowed). (E) The CArG Box 1DS
oligonucleotide also directs premature and broad expression in the stage 22 embryo when placed in front of the 5-103truncation of the cardiac
-actin promoter. (G) Nucleotides spanning 275 to 91 of the cardiac -actin promoter can act as a weak myotome-specific enhancer.
Dorsolateral view of a stage. 25 embryo showing feint, but detectable fluorescence in the myotomes. (NB, Strong fluorescence in the forebrain,
hindbrain, and eyes (arrows) results from the presence of a  crystallin/GFP cotransgene). (A–E) Anterior to left. (G) Anterior at top.
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In an effort to delineate more precisely the nucleotides
downstream of CArG box 1 responsible for restoring expres-
sion in the heart, we next tested CArG box 1 oligonucleo-
tides that included variant flanking sequence. Since the
entire DS sequence except a central C is conserved between
the two amphibian species Xenopus laevis and Xenopus
borealis, we compared mutation of four nucleotides on
either side of this central residue. Two copies of each
oligonucleotide were cloned into the LS10/13 vector. Mu-
tation of the nucleotides most distal to CArG box 1 (variant
R-LS 10/13) had no apparent effect on the expression
pattern in either myotomes or heart (Fig. 3D). Conversely,
alteration of four nucleotides most proximal to CArG box 1
(variant L-LS 10/13) completely abolished transgene expres-
sion within the heart (Fig. 3C). Together, these results
demonstrate that the most proximal CArG box, along with
five nucleotides downstream, are critical for expression of
the cardiac -actin promoter in cardiac muscle of the
embryo.
E Boxes Are Dispensable for Expression of the
Cardiac -Actin Gene in Vivo
We next investigated sequences necessary for transgene
expression in embryonic skeletal muscle. Several previous
studies of the cardiac actin gene have emphasised impor-
tance of E boxes for cell-specific promoter activity, includ-
ing assays using differentiation of cultured myogenic cell
lines and skeletal muscle induction in Xenopus embryo
explants (Mohun et al., 1989b; Sartorelli et al., 1990). Once
again, however, our results with transgenic embryos proved
quite different. Truncation of the promoter region from 580
bp to the most proximal 216 bp removes all E box motifs
along with CArG box 4, yet transgenic embryos showed
GFP expression that was qualitatively indistinguishable
from the full-length promoter (Fig. 2A). Therefore, within
the embryo, sequences distal from 216 are not essential
for correct embryonic expression of the cardiac -actin
gene.
Further truncation to remove all sequences upstream of
CArG box 1 (103) had a profound impact on promoter
activity, severely reducing or abolishing expression in myo-
tomal muscle (Fig. 2B, and data not shown). This transgene
gave variable levels of GFP expression within the heart
along with ectopic expression throughout the head region.
Sequences lying between 580 and 103, encompassing
the E boxes and CArG boxes 2–4, are therefore essential for
proper regulation of the cardiac -actin gene in both myo-
tomal and cardiac muscle.
Sequences Encompassing CArG Boxes 1–4 Are
Required for Strong and Uniform Expression in
Skeletal Muscle
Since removal of sequences upstream of CArG box 4 had
no apparent effect on expression within the myotomes,
while truncation to CArG box 1 severely impaired or
abolished expression in this tissue, we reasoned that the
intervening sequences, while apparently unimportant for
expression in the heart (Figs. 3B–3D), must be important for
myotomal expression. Consistent with this, internal dele-
tion of sequences encompassing CArG boxes 1–4 (LS10/13)
significantly altered transgene expression in the tadpole
myotomes. Instead of uniform, strong expression, staining
for GFP transcripts and GFP fluorescence itself were weak,
appearing stronger in the posterior portion of the embryo
gradient of signal (Fig. 3A, and data not shown). This
resembles the graded expression of the myogenic factors
during normal development (Hopwood et al., 1991, 1992).
Interestingly, replacement of the entire promoter region
containing CArG boxes 1–4 by two copies of the CArG box
1-containing oligonucleotide not only restored transgene
expression within the heart, but also reestablished strong,
uniform expression throughout the myotomes (compare
Figs. 3A and 3B). This result could not be attributed to the
presence of the CArG box 1 sequence alone since a trun-
cated promoter comprising only CArG box 1 and more
proximal sequences (5-103; Fig. 2B) showed little or no
expression in the myotomes. This suggests that normal
expression in striated muscle was restored by the combina-
tion of CArG box 1 and the distal, E-box-containing region
of the promoter.
Taken together, our results suggest that expression of the
full-length cardiac -actin promoter in skeletal muscle
depends on several sequences dispersed throughout the
promoter, none of which is apparently indispensable. In the
absence of more proximal sequences, the most distal region,
containing E box motifs, gives weak and graded expression
along the A-P axis. The presence of proximal sequences
encompassing the CArG boxes is sufficient to establish a
uniform pattern of expression, irrespective of whether dis-
tal sequences are present. Finally, the same result can be
obtained in the absence of such sequences, as long as both
the E-box-containing region and the most proximal CArG
box 1 sequence are present.
CArG Box1  DS Is Sufficient for Expression in the
Myotomes, Head, and Heart Region
Having identified sequences within cardiac -actin pro-
moter that are necessary for expression in the heart and
myotomes, we next asked whether they were also sufficient
to confer appropriate expression upon a heterologous pro-
moter. A fragment encompassing all identified cardiac
-actin regulatory sequences (580/73) gave a pattern of
transgene expression indistinguishable from the endoge-
nous gene when placed upstream of a minimal cytoskeletal
actin promoter (Table 1, and data not shown). We therefore
tested the activity of individual cardiac -actin promoter
elements within the same context.
Three copies of the CArG box1  DS sequence gave a
pattern of expression within the myotomes that was iden-
tical to that obtained with the full-length promoter (Fig.
4A). Expression in the heart region, however, was prema-
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ture, commencing during early tailbud stages (stage 22–24
rather than stage 26); it was also too broad, encompassing
an anteroventral region far larger than the tailbud heart
field (Fig. 4C). By the early tadpole stage (stage 32–34),
expression of this transgene was evident in the myotomes,
the heart, and branchial arches (Fig. 4A).
The expression pattern seen with CArG box 1  DS
sequence could reflect the limited regulatory capacity of
this sequence or it could result from an unexpected inter-
action of this regulatory element with the minimal cy-
toskeletal actin promoter. To differentiate between these
two possibilities, we also tested CArG box 1  DS in front
of a minimal thymidine kinase promoter. Similar results
were obtained with this transgene (Fig. 4B), indicating that
the CArG box 1 and the sequence downstream of it act as an
enhancer active in both the myotomes and a broad anterior
domain of the embryo including the heart. These data also
demonstrate that other sequences within the promoter are
necessary to restrict anterior expression in the embryo to
cardiac and facial (skeletal) muscle.
Interestingly, when we used the same assay to test
mutated versions of the CArG box 1  DS sequence, we
found that alteration of the most proximal sequences vari-
ant L, in which sequences most proximal to CArG box 1
were altered (see Fig. 3) was inactive in the myotomes
(Table 1). This mutation therefore blocks activity of the
CArG box 1  DS sequence as an independent myotome-
specific enhancer, although the variant can still support
transgene expression in the myotomes in the presence of
the distal E-box-containing enhancer (Fig. 3, L-LS10/13).
Promoter Region 275/92, Including CArG Boxes
2–4 Is a Myotome-Specific Enhancer
Our deletion data described above indicate that the pro-
moter region encompassing CArG boxes 2–4 (nucleotides
275/92) is important for expression of the cardiac
-actin promoter in the myotomes. For example, the E-box-
containing distal portion of the promoter can only direct
weak myotomal expression in a posterior-to-anterior gradi-
ent (Fig. 3A), yet specific mutation of CArG box 1 within
the full promoter (LS29; Fig. 2D) leaves the normal, uniform
expression in the myotomes unaffected. We therefore tested
the activity of promoter region 275/92 when fused
TABLE 1
Summary of Transgenesis Experiments
Transgene promoter Insert Insert copy no. Embryos analysed Figure
Cardiac 5-216 — NA 16/107 2A
Cardiac LS29 — NA 34/109 2D
Cardiac LS13 — NA 42/81 2E
Cardiac LS25 — NA 11/43 2C
Cardiac LS 10/13 — NA 16/40 3A
Cardiac LS 10/13 (CArG box1  DS) 2 64/177 3B
Cardiac LS 10/13 (CArG box1 R) 2 54/109 3D
Cardiac LS 10/13 (CArG box1 L) 2 15/30 3C
Cardiac LS 10/13 (CArG box1 T) 2 12/35 3E
Cardiac LS 10/13 (SRE) 1 7/15 7A
Cardiac LS 10/13 (SRE) 2 12/40 7B,C
Minimal cyt. actin Cardiac prom 580/73 1 10/25 n/s
Minimal cyt. actin Cardiac prom. 275/91 1 10/37 4G
Minimal cyt. actin (CArG box1  DS) 3 66/261 4A,C
Minimal cyt. actin (CArG box1 L) 3 0/20* n/s
Minimal cyt. actin E  CArG box1  DS 3 28/124 4D
Minimal cyt. actin (CArGbox1 T) 3 2/12* n/s
Minimal cyt. actin (E box) 3 3/15 n/s
Minimal cyt. actin (CArG box1 m5) 3 0/15* n/s
Minimal cyt. actin (CArG box1 m6) 5 2/13* n/s
Minimal cyt. actin (SRE) 3 4/14 7D,E
Cardiac 5-103 — NA 5/30 2B
Cardiac 5-103 (CArG box1  DS) 3 7/8 4E
Cardiac 5-103 (E  CArG box1  DS) 3 22/47 4F
Note. Each GFP transgene promoter construct used in the study is listed along with any inserted DNA sequence and its copy number
within the promoter. Oligonucleotide insertions (detailed in Materials and Methods) are shown in parentheses. For each construct, the total
number of embryos showing GFP expression is shown along with the total of developing embryos. In some experiments (*), inclusion of
a -crystallin/GFP cotransgene allowed selection of transgenic embryos, and in such cases, this total is shown. n/s, not shown; NA, not
applicable.
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upstream of the minimal cytoskeletal actin promoter. The
resulting transgene showed weak but uniform expression in
the myotomes (Fig. 4G), indicating that the 275/92
region, encompassing CArG boxes 2–4, can act indepen-
dently, as a myotome-specific enhancer. The combination
of strong and uniform expression seen in the myotomes of
LS29 transgenic embryos presumably results from the com-
bined activities of this enhancer and sequences within the
distal, E-box-containing portion of the promoter.
Regulatory Interactions between Distal and
Proximal Enhancers
Two distinct effects of the distal, E-box-containing region
of the promoter can be distinguished in our results. In
isolation, this region acts as a weak myotomal-specific
enhancer (see above), but a second activity is detected using
constructs that combine this region with the CArG box
1  DS sequence. Such transgenes show correct spatiotem-
poral restriction of transgene expression in the heart, rather
than the more widespread expression throughout the head
region displayed by constructs containing the CArG
box1-DS sequence alone (Fig. 3B). The distal enhancer thus
appears to restrict expression driven by the proximal CArG
box 1 enhancer. We therefore tested whether either of these
results could be replicated by using an E-box oligonucleo-
tide rather than the entire distal region of the cardiac
-actin promoter.
Three copies of the principal functional E-box motif
(Mohun et al., 1989b; Taylor et al., 1991) placed in front of
the cytoskeletal actin promoter gave rise to an expression
pattern similar to that attributable to the entire distal
promoter region (Table 1, and data not shown). In contrast,
a transgene comprising the E-box motif directly adjacent to
the CArG box 1  DS sequence on either the minimal
cytoskeletal or cardiac actin promoters gave strong, uni-
form myotomal expression (Figs. 4D and 4E). This is similar
to that obtained with CArG box 1  DS sequence alone,
suggesting either that the effects of the two myotome
enhancers is additive or that the activity of the CArG box
1  DS sequence predominates. However, such a synthetic
promoter did not recapitulate the entire expression pro-
gramme of the cardiac actin promoter. No detectable expres-
sion was obtained with this promoter either in the heart, or
in ectopic sites within the head (Figs. 4D and 4F). One
explanation for this may be inappropriate spacing between
the E-box and CArG box 1 motifs; alternatively, sequences
present in the distal enhancer (580/216), but absent in
the E-CArG box 1  DS oligo, may also be required for the
interactions necessary for expression in cardiac muscle. We
cannot yet distinguish between these alternatives.
Interactions Mediated by E-Boxes and CArG Sites
also Restrict Activity in Serum-Induced Fibroblasts
Our finding of a regulatory interaction mediated by the
combination of E-box and CArG box sites in embryonic
muscle prompted us to ask whether the same sequences
might also be responsible for regulating transcription of the
cardiac -actin promoter in other contexts. We have previ-
ously shown that the CArG box 1 sequence of the cardiac
-actin gene can replace the related SRE motif of the c-fos
proto-oncogene promoter and mediate transcriptional in-
duction of c-fos by serum response factor (Taylor et al.,
1989). However, transcription of striated muscle-specific
genes containing CArG boxes, such as cardiac -actin, is
not induced in fibroblasts by serum growth factors and we
FIG. 5. E-boxes mediate silencing of cardiac -actin promoter in
serum-stimulated fibroblasts. NIH3T3 fibroblasts were transfected
with test plasmids comprising the human c-fos gene driven by the
full-length c-fosh promoter (Fos-711) or a chimeric promoter con-
taining cardiac actin promoter sequences fused upstream of the
c-fosh 5-100. Three cardiac actin promoter regions were tested;
the full-length promoter ( 580), a 5 truncation that removes the
E-box motifs (246), and an internal deletion of the 580-bp pro-
moter that removes 31 bp encompassing the three E-box motifs
(M). Cells were serum-starved () and then stimulated with
serum for 40 min (). Total RNA was analysed by RNase protec-
tions. M-DNA markers; P-undigested riboprobes; C-probes hybri-
dised to tRNA. Diagrams showing essential features of test plas-
mids are shown below the gel. Protected Fos and globin transcripts
are indicated.
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therefore sought to establish what might restrict SRF activ-
ity on such promoters.
Using a serum induction assay, we found that a chimeric
reporter comprising a 580-bp region of the cardiac -actin
promoter fused to the c-fosh gene remained transcription-
ally inactive in transfected fibroblasts (Fig. 5). In contrast, 5
truncations (-246) or an internal deletion (M) that re-
moved the E-boxes from the cardiac -actin promoter
portion resulted in rapid induction by serum growth factors.
These results demonstrate that, in two distinct contexts,
(embryonic muscle differentiation and serum induction of
fibroblasts), the activity of SRF at its CArG box 1/SRE
binding site is modulated by factors binding to distal E-box
motifs of the cardiac -actin promoter.
Functionally Impaired CArG Box 1 Mutants Have
Reduced Affinity for SRF
We have observed that mutating sequences downstream
of CArG box 1 results in loss of heart expression from the
full-length cardiac -actin promoter (LS13; Fig. 2E) and
gives a similar result when tested with heterologous pro-
moters (CArG-L; Fig. 3C). One explanation could be that
such mutations impair the binding of an essential, regula-
tory transcription factor. However, we have been unable to
identify any consistent, qualitative difference in the capac-
ity of wild-type and CArG-L variant sequences to bind
proteins in embryonic extracts, despite testing a variety of
binding conditions and extract preparation procedures (data
not shown). We have, however, consistently observed a
lower apparent affinity of the CArG-L variant for SRF
present in embryo extracts (as identified by anti-SRF anti-
bodies), suggesting that the effect of such mutations is to
reduce SRF binding to CArG box 1 (data not shown). This
effect is evident both in direct binding of each sequence to
recombinant SRF (Fig. 6A) and from competition assays
(Fig. 6B).
Reduced Affinity CArG Variants Are Not
Expressed in Cardiac Muscle
Mutation of the A/T rich core within CArG box 1 to an
all-T sequence had little effect on the ability of the motif to
interact with the distal enhancer of LS10/13, as judged by
uniform expression in the myotomes (Fig. 3E; T-LS10/13).
However, this construct gave no expression within the
developing tadpole heart, indicating that the core region of
the CArG box 1 is important for its function as heart
enhancer. In the absence of the upstream enhancer provided
by the LS 10/13 promoter construct, CArG-T oligonucleo-
tides, including the downstream DS element, were inca-
pable of supporting any detectable transgene expression
from the minimal cytoskeletal actin promoter (data not
shown; Table 1). Two additional constructs that introduce
less radical changes in A/T-rich core of the CArG box 1 (Fig.
6C; mutations m5 and m6) were also tested by using the
heterologous promoter assay. Mutation of two A residues in
the proximal half of the core (mutation m5) showed no
expression in the embryo. Mutation of the distal three A
residues (mutation m6) also generally showed lack of ex-
pression, although occasional embryos showed very weak
expression in the myotomes and heart region. This may
reflect an intrinsic difference between the two mutations,
but may also be a consequence of the increased oligonucle-
otide copy number (5 rather than 3) in the m6/cyt/GFP
transgene. When either mutant sequence was tested for SRF
binding in a competition assay, each showed an affinity for
the protein which was significantly reduced from that of
the wild-type sequence, although somewhat greater than
the CArG-L variant (Fig. 6).
These results suggest that a reduction in affinity of the
CArG box 1 sequence for SRF can specifically block expres-
sion of the cardiac promoter within the developing heart.
Such reductions can be achieved by mutations within the
CArG box itself, (CArG-T, m5, and m6). They can also be
obtained by mutations within adjacent downstream se-
quences (LS13, CArG-L) which are not thought to be
involved in specific binding to SRF (Pellegrini et al., 1995).
If this interpretation is correct, as long as no other factors
required for the CArG-SRF interaction are limiting, it
should be possible to activate the low affinity, inactive
CArG-L variant simply by increasing concentration of SRF.
Consistent with this, coinjection of the lower affinity
CArG-L cyt/GFP reporter with CMV-SRF greatly increased
both the frequency of GFP-expressing embryos and their
levels of expression (Fig. 6D). These results suggest that the
high affinity of SRF for the CArG box 1 sequence is itself a
major determinant of cardiac -actin regulation.
The c-fos SRE Can Replace CArG Box 1 in the
Cardiac -Actin Promoter
As a further test of the role of CArG box as SRF binding
site, we examined whether a heterologous, high-affinity
SRF binding site could interact with the distal, E-box-
containing enhancer of cardiac -actin promoter to restore
normal expression on the LS10/13 internal deletion con-
struct. Using the SRE sequence from the c-fos gene, which
has different core and flanking sequences from CArG box 1,
we compared the activity of transgenes containing either
one or two copies of the SRE oligonucleotide with that
obtained from two copies of the wild-type CArG box 1
sequence (Fig. 3). Constructs containing a single copy of the
SRE gave uniform expression in the myotomes with no
other sites of expression (Fig. 7A). Such a pattern of expres-
sion was also seen with two copies of the CArG-L variant
(Fig. 3C) and with a single copy of the wild-type CArG box
1 (data not shown). In contrast, constructs containing two
copies of the SRE were also expressed in other regions of the
embryo. In approximately half the cases (5/12), this addi-
tional expression was observed only in the heart (Fig. 7B),
indicating that the c-fos SRE can indeed interact with the
distal enhancer from cardiac -actin gene to direct expres-
sion to myotomes and heart. In the remaining embryos, two
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copies of the SRE yielded a broader pattern of expression,
encompassing heart and branchial arches (Fig. 7C).
A simple explanation of these results is that their out-
come reflects the relative affinities of CArG box 1/SRE
variants for SRF and the distribution of SRF within the
embryo. To investigate the latter, we used whole-amount in
situ hybridisation to determine the distribution of SRF
RNA in Xenopus embryos. In the late neurula (stage 19),
whole-mount in situ hybridisation indicates that SRF
mRNA is present at the highest levels in the somites. A
lower level is detected in the anterior region of the embryo,
including the heart field (Figs. 7F and 7G) and still lower
levels can be detected uniformly in the surface ectoderm. In
the hatching tailbud (stage 26), expression is strongest in
the myotomes and presumptive heart tube, but is readily
detectable in the head (Fig. 7H). By stage 33, strong sites of
expression are evident throughout the embryo, including
the myotomes, heart, body wall musculature, branchial
arches, and restricted areas of the brain. Lower levels of SRF
mRNA remain in the pronephros and in surface ectoderm
(Figs. 7I and 7J).
The distribution of active SRF protein need not, of course,
match the distribution of its transcripts and we have no
quantitative assay of SRF distribution. However, we might
expect that transgenes driven by multimerised, high-
affinity SRF binding sites such as the c-fos SRE, or its even
higher affinity variant, ACTL (Taylor et al., 1989), would
act broadly as sensors for SRF localisation. The expression
of such transgenes is indeed similar to that found for SRF
RNA distribution (Fig. 7E, and data not shown).
In this interpretation, when CArG box 1 variants with
lower affinity (such as CArG-L and CArG-T) are cloned into
the CArG-deficient promoter LS10/13, the resulting trans-
genes show expression in myotomes, but not heart, because
the tadpole myotomes have higher levels of SRF expression
than the developing cardiac muscle. Higher affinity variants
(such as the wild-type CArG box 1-DS sequence or the c-fos
SRE) give correct expression in both myotomes and heart.
The c-fos SRE appears to have a higher affinity for SRF than
the CArG box 1 sequence in vitro (Taylor et al., 1989) and
the widespread expression that can also be obtained when
two copies of the c-fos SRE are present may then simply
reflect the ability of such transgenes to respond to even
lower levels of SRF in a wide range of other tissues in the
embryo. Consistent with this view, three copies of the c-fos
SRE in front of the cytoskeletal actin promoter result in a
pattern of expression which is broader then expression
driven by three copies of the CArG box 1-DS sequence
(compare Figs. 7D and 7E with Figs. 4A and 4B).
DISCUSSION
Regulation of Expression in the Heart by SRF
Our promoter analysis shows that not only is the CArG
box 1 and its adjacent 5 bp downstream necessary for
expression of the Xenopus cardiac -actin gene in the heart,
when multimerised it is also sufficient for expression in
both the myotomes and anterior part of the embryo, includ-
ing the heart. This sequence presents the only candidate
“heart-specific” enhancer within the 580-bp promoter re-
gion. Intriguingly, our data suggest that the role of this
sequence may be relatively simple, acting as high-affinity
SRF binding site rather than functioning as a composite site
for SRF and other accessory proteins. We base this conclu-
sion on the following three observations. Mutations of the
5 bp adjacent to the CArG box or within the A/T-rich core
affect transgene expression in the heart and lower affinity of
the CArG sequence for SRF (Fig. 6). A heterologous, high-
affinity CArG box can interact with the distal enhancer
from cardiac -actin gene in manner similar to that of the
native CArG box 1 sequence, resulting in correct expression
in both the myotomes and heart (Fig. 7). Finally, the
low-affinity, functionally impaired CArG box 1 variant
CArG-L can be activated in embryos by providing exog-
enous SRF (Fig. 6).
This is a surprising finding because SRF has been impli-
cated in regulation of many striated and smooth muscle
genes, as well as in regulation of a subset of cellular
immediate-early genes. Previous studies of such genes have
defined CArG/SRE box-adjacent sequences that provide
specificity of regulation through the accessory factors that
bind them. The best example of this is provided by the c-fos
SRE and ternary complex factors from ETS family (Treis-
man, 1994). We cannot, of course, exclude the possibility
that nucleotides adjacent to CArG box 1 act as a binding
site for a factor that modulates CArG box 1 function.
However, it is striking that these sequences are poorly
conserved amongst the cardiac -actin genes of vertebrates
and it is difficult to reconcile such variation with the
presence of a common binding site. Furthermore, since a
heterologous SRE can productively interact with the distal
enhancer of cardiac -actin gene, if the DS sequence adja-
cent to CArG box 1 is indeed a binding site for an additional
factor, it cannot be an essential heart-specific cofactor of
SRF.
Our data show that the DS sequence affects the affinity of
SRF for CArG box 1, most likely by modulating the struc-
ture of the binding site. In the dystrophin promoter, a
CArG-adjacent sequence essential for muscle-specific ex-
pression acts as a binding site for a factor that induces DNA
bending (Galvagni et al., 1997). Similarly, the DS sequence
could affect the affinity of SRF for the cardiac actin pro-
moter by modulating the structure of CArG box 1. If so,
then such an interaction is either unnecessary with the
heterologous c-fos SRE, or is supported by nucleotides
included with this binding site, despite the apparent lack of
sequence similarity.
Whether mutation of the DS sequence results in a change
in the affinity of SRF for CArG box 1 or a change in CArG
box 1 conformation, or both, such changes abolish heart-
specific expression. This could be a direct consequence of
reduced SRF binding or it may result from an indirect effect
on the association of SRF with an accessory factor which
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does not itself bind DNA but is nevertheless essential for
heart-specific expression. An example of such a factor is
myocardin, a recently described transcriptional activator.
Myocardin cooperates with SRF on muscle-specific promot-
ers bearing multiple CArG boxes, but not on the c-fos
promoter, which has a single CArG box (Wang et al., 2001).
It is noteworthy that in our experiments, correct cardiac
expression was indeed only restored to transgenes when
more than one CArG box motif was present in the trans-
gene promoter (Figs. 3 and 7).
Recently, transgenic mouse studies have investigated
regulatory capacity of isolated CArG boxes from smooth-
muscle specific SM22 gene and c-fos (Chang et al., 2001;
Strobeck et al., 2001). Chang et al., (2001) found that the
high-affinity c-fos SRE directs widespread expression
within the embryo, whereas the lower affinity CArG box
from the SM22 gene directs expression only in muscle cell
types which are sites of high SRF expression. These results
match our findings with transgenic frog embryos. In con-
trast, Strobeck et al., (2001) found that an isolated SRE has
no activity. The explanation for this discrepancy is unclear,
but may in part result from the differing minimal promoters
used in the transgenes.
Enhancer Interactions in the Cardiac -Actin
Promoter
Our studies have identified three distinct enhancers that
are involved in regulation of cardiac -actin in the somites
and subsequently in the myotomes. The distal enhancer,
containing three E-boxes, drives expression in a posterior-
to-anterior gradient, resembling the expression of endoge-
nous myogenic bHLH factors (Hopwood et al., 1991, 1992).
CArG box 1  DS, discussed above, is an enhancer that
gives uniform expression in the myotomes, when present in
three copies. Finally, region including CArG boxes 2-4 will
confer weak and uniform expression in the myotomes only.
Interaction between any pair of these enhancers results in
strong, uniform expression in the myotomes.
Expression in cardiac muscle of the embryo appears to
FIG. 6. CArG box 1 variants with impaired activity in vivo have low affinity for SRF in vitro. (A) Designated probes of equal specific
activity and integrity (lower panel, 8% native polyacrylamide gel) were incubated with SRF obtained from coupled transcription-translation
reactions. Protein–DNA complexes were resolved on 6% native acrylamide gels. (B) The relative affinities of variant CArG box 1 sequences
for SRF were examined by testing the ability of a 20-, 50-, and 100-fold molar excess of unlabelled oligonucleotides to compete with the
wild-type CArG box 1 probe. (C) Oligonucleotide sequences tested. The relative activity of these enhancer elements when tested by
transgenesis using the minimal cytoskeletal actin promoter is indicated. (Embryos were scored at the tadpole stage.) All constructs (detailed
in Fig. 4 and Table 1) had three copies of oligonucleotides, except m6, which contained 5 copies (D) Exogenous SRF can activate L-cyt/GFP
in embryos. Fertilised embryos were injected with 100 pg of L/cyt/GFP and CMV or CMV-SRF DNAs at 5:1 ratio, and embryos were scored
for GFP activity from stage 19 onwards.
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result from further interactions between the most proximal
and distal enhancers. While multimerised copies of the
CArG box 1  DS sequence will result in transgene expres-
sion in the heart, expression is not restricted to this tissue
but is detected more broadly throughout the head region
and commences prematurely. Addition of the E-box-
containing enhancer appears to block expression of the
transgene in ectopic sites within the head, yielding a
pattern comparable with that of the endogenous cardiac
-actin gene (compare Figs. 4A and 4B with Fig. 3B).
Our experiments do not identify the critical sequence(s)
within the distal promoter necessary for this interaction. As
a myotome-specific enhancer, the E-box sequence itself is
comparable with the entire distal region (Table 1). Further-
more, we have found that in an another regulatory context
(the serum-stimulation of fibroblasts), interactions between
factors binding at the E-box and CArG box 1 sites are indeed
responsible for restricting expression from cardiac -actin
promoter. However, we were unable to replicate the inter-
action between distal and proximal enhancers of the pro-
moter using oligonucleotide copies of the E-box and CArG
box 1 motifs. Replacement of the entire E-box-containing
enhancer with an E-box motif immediately adjacent to the
CArG box 1  DS sequence blocked all expression in the
head region, whether ectopic or cardiac restricted, whilst
myotomal expression was unaffected (Fig. 4). We do not
understand why expression of the transgene is selectively
affected in this way but it may indicate that expression in
myotome and cardiac muscle is affected quite differently by
the precise distance or configuration of the E-box and CArG
box binding sites.
Comparison with Previous Studies
of Cardiac -Actin
In transgenic mice, the proximal portion of the cardiac
-actin promoter is sufficient for proper expression in
embryos but inadequate for appropriate expression in post-
natal mice (Biben et al., 1996). Our results are strikingly
similar. Transgenes containing sequences of the Xenopus
promoter up to 580 are appropriately expressed in Xeno-
pus embryos and tadpoles, but do not appear to be expressed
in the heart muscle of adult frogs (B.L. and T.M., unpub-
lished results). A notable difference between our studies
and earlier work is our finding that E-box sequences are
dispensable. For example, in cell transfection studies, the
E-box was found to be critical for activity of human cardiac
-actin promoter (Sartorelli et al., 1990). Similarly, our
earlier studies in Xenopus employing a muscle induction
assay also identified the distal E-box region as essential for
expression in somitic muscle (Mohun et al., 1989b). Our
earlier studies also found that CArG box 1 was necessary for
activity of cardiac -actin reporter in induced muscle tissue
(Mohun et al., 1989b), while our transgenic studies indicate
that it is only required for heart expression (Fig. 2). At
present, we cannot adequately account for these discrepan-
cies but note the profound differences between the in vivo
and in vitro assays employed, in particular the chromo-
somal vs episomal status of the reporter DNA. Another
FIG. 7. c-fos SRE activity in embryos can be restricted to heart and
myotomes by interaction with the distal enhancer from the cardiac
-actin gene. (A) A single copy of the SRE together with the 580/
275 enhancer can direct uniform expression of GFP in the myo-
tomes, but not in the heart. Two copies of the SRE in this context also
direct expression of GFP in the heart, resulting either in the correct
pattern of expression for the cardiac -actin promoter (B) or a signifi-
cantly broader expression pattern (C). With three copies of c-fos SRE,
transgenic embryos show widespread expression of GFP, encompass-
ing the myotomes, head, heart, and pronephric region (D, E). Lateral
view of stage 32 embryos, anterior to the right. (F–J) Expression pattern
of endogenous SRF mRNA. (F) Lateral view of a stage 19 embryo
showing strong expression in the somites, intermediate expression
levels in ventroanterior region (arrow), and low uniform level of
expression in the surface ectoderm. (G) Dorsal view of the same
embryo. (H) Stage 26 embryo, showing expression of SRF mRNA in
the myotomes, future heart (arrow) and head. (I) Stage 30 embryo
showing SRF mRNA in the heart and branchial arches. (J) Stage 33
embryo, with SRF mRNA now also detectable in the body wall
muscles (arrows) and distinct regions in the brain. (Anterior to the
right in all panels, except F and G, where anterior is to the top).
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potential basis for discrepancies may be the nonquantita-
tive nature of GFP transgenic expression.
Previous studies have suggested that multiple CArG
boxes are required for activation of the chick skeletal and
cardiac actin genes (Chen et al., 1996; Lee et al., 1991).
Interaction between multiple CArG boxes within these
promoters apparently leads to cooperative binding of SRF
(Lee et al., 1991). In the chick cardiac actin promoter, such
cooperative binding might displace repressor YY1 from its’
sites within CArG boxes 2 and 3 and thereby contribute to
overall activity of the promoter (Chen and Schwartz, 1996).
In our study, we have also found that CArG boxes 2-4 can
interact with CArG box 1 to direct appropriate expression
from the Xenopus cardiac actin promoter, but we do not yet
know whether this results from cooperative binding of SRF.
As in the chick promoter, potential YY1 sites are present
within Xenopus CArG boxes 2 and 3, but whether YY1
plays a role in regulating the Xenopus promoter remains to
be established
CArG boxes are required for regulation of all cardiac
-actin genes studied. They have been shown to interact
with several adjacent sequences: SP1 and E-box in human
cardiac -actin (Biesiada et al., 1999; Sartorelli et al., 1990);
Nkx2.5 and E-boxes in the chick gene (Chen et al., 1996;
Chen and Schwartz, 1996). With the Xenopus gene, we have
no evidence indicating a role for SP1, binding either directly
or through modulation of SRF binding (data not shown).
Nor are any consensus Nkx2.5 binding sites present in the
580-bp portion of the Xenopus cardiac -actin promoter.
However, as the reported interaction of Nkx2.5 and SRF
occurs in the absence of DNA binding by Nkx2.5 (Chen and
Schwartz, 1996), we cannot rule out participation of
Nkx2.5, or any such SRF-accessory factor. A conserved
feature of cardiac -actin gene regulation in different spe-
cies appears to be the interaction of CArG box motifs with
other site(s). In future, it will be of great interest to
determine how the regulatory interactions we have de-
tected occur, and to determine whether similar mecha-
nisms regulate other striated muscle-restricted and cardiac-
specific genes.
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